- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
XtalPi, Eli Lilly Announce AI Robotics Collaboration
Partnership to focus on drug discovery platform.
XtalPi, a pharmaceutical technology company, has announced an AI drug discovery collaboration with Eli Lilly, receiving up to $250 million in milestone payments. Per the agreement, XtalPi will utilize its robotics platform in order to deliver drug candidates for an undisclosed target.
"With a closed loop of AI and quantum physics algorithms working in sync with the data factory of large-scale robotics experiments, XtalPi is uniquely equipped to tackle challenging novel targets,” said Dr. Jian Ma, CEO of XtalPi. “We are honored that Lilly has chosen XtalPi’s AI + robotics drug R&D platform as a partner in achieving more fruitful pharmaceutical innovation and bringing much-needed treatments to patients worldwide."
Reference: XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics. May 30, 2023/Xpalti
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
